Boston Scientific Becomes Only Company With Two Drug-Eluting Stent Platforms With European Approval of Everolimus-Eluting PROMUS(TM) Stent System
NATICK, Mass--18 Oct--PRNewswire-AsiaNet/InfoQuest
PROMUS stent to complement Company's market-leading TAXUS(TM) stent systems
Boston Scientific Corporation (NYSE: BSX) announced today that the PROMUS(TM) everolimus-eluting coronary stent system has received CE Mark approval, making Boston Scientific the only company to offer two distinct approved drug-eluting stent (DES) platforms in the CE geographies. This approval allows Boston Scientific to begin marketing the new DES in the 25 countries of the European Union and will support market registrations in other regulated countries in Asia, Latin America and Eastern Europe.
The PROMUS stent is a private-labeled Xience(TM) V Everolimus-Eluting Coronary stent system manufactured by Abbott and distributed by Boston Scientific. It will complement Boston Scientific's market-leading TAXUS(TM) paclitaxel-eluting stent systems. The Company expects to launch the PROMUS stent in Europe in 2007.
"We are very pleased that CE Mark approval has been granted for this important expansion of our drug-eluting stent portfolio," said Paul LaViolette, Boston Scientific Chief Operating Officer. "Boston Scientific is proud to be able to offer clinicians the choice of a paclitaxel-eluting stent and an everolimus-eluting stent from the same company, for the first time. We look forward to complementing the proven safety and efficacy of TAXUS with the tremendous potential of PROMUS, further demonstrating the breadth and depth of our DES pipeline as well as our overall leadership in supplying innovative products to interventional cardiologists."
Boston Scientific's TAXUS stent system has a record of proven outcomes, including over three million TAXUS stents implanted in patients worldwide and clinical follow-up on nearly 3,500 patients out to four years in TAXUS randomized, controlled clinical trials. Positive results for the Xience V stent were reported from the SPIRIT II clinical trial at the recent World Congress of Cardiology in Barcelona, Spain, showing that the Xience V stent met its primary endpoint of non-inferiority to TAXUS as measured by late loss at six months.
PROMUS and TAXUS are trademarks of Boston Scientific Corporation or its affiliates. Xience V is a trademark of Abbott. The SPIRIT Clinical Program is sponsored by Abbott Vascular. PROMUS is not approved for sale in the U.S.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings
SOURCE: Boston Scientific Corporation
CONTACT: Geraldine Varoqui,
Boston Scientific PR Manager International,
+49-2102-489-461,
[email protected] ; or
Tracy Paul,
BSC press office,
+44-20-7413-3101,
Web site: http://www.bostonscientific.com\
--Distributed by AsiaNet ( www.asianetnews.net )--
ข่าวthe European Union+Boston Scientificวันนี้
LIV-24 applies ESG Tech AI technology, revolutionising industrial sector Cuts costs, increases productivity, facilitates sustainable business
At present, many countries, especially members of the European Union, have imposed the so-called Carbon Border Adjustment Mechanism (CBAM) that mandates the issuance of carbon emission certificates (CBAM certificates) effectively certifying the actual amount of carbon emission from the production process of a certain product. This process is designed to prevent the import of products with high greenhouse gas emissions from entering the EU zone. Such Environmental, Social and Governance (ESG)
TAT and International Partners Urge Thai Businesses to Prepare for Imminent EU Regulations on Sustainable Tourism
—
On September 26, at the Avani+ Riversi...
International efforts to protect and empower ASEAN's women migrant workers
—
International organisations under the United Nations (UN) and the European Un...
Artmarket.com: France obtains the maintenance of VAT at the reduced rate of 5.5% on the Art Market, a major victory with very considerable advantages according to Artprice.
France's art market professionals will be extremely relieved by this news. The French government has decided to maintain the VAT...TerraPay Group Expands Business Operations in Italy and Sets Sights on European Union
TerraPay, a leading global payments infrastructure company, today announced that it has secured authorization as an Electronic Money Institute (EMI) in Italy. Having obtained approval from the Bank of Italy,...
EXPORT PROMOTION SEMINAR TO HIGHLIGHT EXCELLENCE OF EUROPEAN FOOD
—
H.E. Mr. David Daly, Ambassador of the European Union to Thai (EU) is set to host a tw...